ARTICLE | Top Story
Multiple myeloma data on parade at ASCO
May 15, 2015 1:14 AM UTC
A series of abstracts released ahead of the American Society of Clinical Oncology (ASCO) meeting revealed efficacy data from studies of multiple myeloma compounds elotuzumab from AbbVie Inc. (NYSE:ABBV) and Bristol-Myers Squibb Co. (NYSE:BMY); Kyprolis carfilzomib from Amgen Inc. (NASDAQ:AMGN); and venetoclax (ABT-199) from AbbVie and Roche (SIX:ROG; OTCQX:RHHBY).
In the Phase III ELOQUENT-2 trial to treat relapsed or refractory MM, elotuzumab plus Revlimid lenalidomide and dexamethasone led to a 30% reduction in risk of disease progression or death compared to Revlimid and dexamethasone alone. ...